Table 2.
Characteristics of included participants
| Participant characteristic | Treatment (N = 600) | Control (N = 583) |
|---|---|---|
| Age (yr) | ||
| Median | 61.5 | 62 |
| Range | 23–78 | 30–85 |
| Sex, n (%) | ||
| Male | 512 (86) | 478 (82) |
| Female | 86 (14) | 103 (18) |
| Unknown | 2 (<1) | 2 (<1) |
| pT stage, n (%) | ||
| pT0 | 8 (1) | 4 (<1) |
| pT1 | 33 (6) | 23 (4) |
| pT2 | 115 (19) | 114 (20) |
| pT3 | 305 (51) | 303 (52) |
| pT4a | 96 (16) | 94 (16) |
| Other | 9 (1) | 17 (2) |
| Unknown | 34 (6) | 28 (5) |
| pN category, n (%) | ||
| pN0 | 324 (54) | 331 (57) |
| pN1 | 131 (22) | 130 (22) |
| pN2 | 125 (21) | 108 (19) |
| pN3 | 4 (<1) | 0 |
| Unknown | 16 (3) | 14 (2) |
| Performance statusan (%) | ||
| 0 | 223 (66) | 210 (64) |
| 1 | 78 (23) | 85 (26) |
| 2 | 3 (<1) | 3 (1) |
| Unknown | 35 (11) | 31 (9) |
a
Performance status was available for four of the ten trials (56% of participants).